Report Overview
Inactivated vaccines for Swine Mycoplasma pneumonia are also available. They are made by using inactivated or killed strains of the bacteria to stimulate an immune response in pigs without causing disease.
This report provides a deep insight into the global Inactivated Vaccine for Swine Mycoplasma Pneumonia market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
MARKET SHARES
THE GLOBAL INACTIVATED VACCINE FOR SWINE
MYCOPLASMA PNEUMONIA MARKET SIZE WAS ESTIMATED AT USD 342 MILLION IN 2024 AND IS PROJECTED TO REACH USD 650.23 MILLION BY 2032, EXHIBITING A CAGR OF 7.40% DURING THE FORECAST PERIOD.
NORTH
AMERICA INACTIVATED VACCINE FOR SWINE
MYCOPLASMA PNEUMONIA MARKET SIZE WAS ESTIMATED AT USD 100.78 MILLION IN 2024, AT A CAGR OF 6.34% DURING THE FORECAST PERIOD OF 2025 THROUGH 2032.
KEY COMPANY
•ZOETIS
•BOEHRINGER INGELHEIM
•JINHE BIOTECHNOLOGY
•MERCK
•HIPRA
•CEVA SANTÉ ANIMALE
• Market Segmentation (by Type)
Single Vaccine
Dual Vaccine
Market Segmentation (by Application)
Geographic Segmentation
•North America (USA, Canada, Mexico)
•Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
•Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
•South America (Brazil, Argentina, Columbia, Rest of South America)
•The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
